Tukysa Unión Europea - español - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - agentes antineoplásicos - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

CANDESARTAN/HIDROCLOROTIAZIDA RATIOPHARM 32mg/12,5 mg COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

candesartan/hidroclorotiazida ratiopharm 32mg/12,5 mg comprimidos efg

teva pharma s.l.u. - candesartan cilexetilo; hidroclorotiazida - comprimido - 32 mg/12,5 mg - candesartan cilexetilo 32 mg; hidroclorotiazida 12,5 mg - candesartán y diuréticos

CANDESARTAN/HIDROCLOROTIAZIDA RATIOPHARM 32mg/25 mg COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

candesartan/hidroclorotiazida ratiopharm 32mg/25 mg comprimidos efg

teva pharma s.l.u. - candesartan cilexetilo; hidroclorotiazida - comprimido - 32 mg/25 mg - candesartan cilexetilo 32 mg; hidroclorotiazida 25 mg - candesartán y diuréticos

Temozolomide Sun Unión Europea - español - EMA (European Medicines Agency)

temozolomide sun

sun pharmaceutical industries europe b.v. - temozolomida - glioma; glioblastoma - agentes antineoplásicos - la temozolomida sun está indicado para el tratamiento de:adultos pacientes recién diagnosticados de glioblastoma multiforme de forma concomitante con radioterapia (rt) y, posteriormente, como monoterapia para el tratamiento;los niños desde la edad de tres años, adolescentes y pacientes adultos con glioma maligno, tal como glioblastoma multiforme o astrocitoma anaplásico, que muestra la recurrencia o progresión después de la terapia estándar.

Ertapenem SUN Unión Europea - español - EMA (European Medicines Agency)

ertapenem sun

sun pharmaceutical industries (europe) b.v. - ertapenem sodio - infecciones bacterianas - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 y 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.

Sitagliptin / Metformin hydrochloride Sun Unión Europea - español - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapia de combinación triple) como complemento a la dieta y ejercicio en pacientes inadecuadamente controlados en su máxima dosis tolerada de metformina y una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

SULFADIAZINA DE PLATA DENVER FARMA Argentina - español - ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)

sulfadiazina de plata denver farma

denver farma s.a. - lidocaina - pomada - crema dermica - lidocaina 0.666 g %; vitamina a 248.000 ui %